RE: Mologic news24 Apr 2020 12:50
Mologic launches laboratory-based diagnostic test for COVID-19
Download PDF Copy
View Supplier Profile
Apr 24 2020
Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, today announced that it will begin manufacturing its laboratory diagnostic test for COVID-19. Following successful independent validation by the Liverpool School of Tropical Medicine and St George’s, University of London, the test has also been submitted to Public Health England for formal validation.
Mologic has entered into a Material Transfer Agreement with Omega Diagnostics Ltd (“Omega”) and Omega will immediately start manufacture of Mologic’s first-generation ELISA diagnostic tests. The laboratory-based ELISA diagnostic test is expected to produce up to 46,000 results per day, potentially contributing a significant portion of the UK government’s planned 100,000 tests per day.
Related Stories
Mologic begins clinical trial to evaluate urine-based diagnostic for cystic fibrosis
Mologic and partners begin validation process for COVID-19 point-of-need diagnostic test
Mologic launches new lab-based COVID-19 antibody tests
Mologic will make the technology and materials for its tests available for use in Africa through a partnership with the Institut Pasteur de Dakar in Senegal, in order to support efforts to contain the pandemic on the continent. The availability of fast, reliable diagnostics for COVID-19 has been identified as a critical opportunity to facilitate contact tracing and “flatten the curve” of the global pandemic.
Since March, leading laboratories across the world have partnered with Mologic to evaluate a variety of diagnostic prototypes and independently assess performance. Results have now been submitted to Public Health England for review. While the assessment and optimization has been expedited, it is vital that any prototype device for COVID-19 is subject to rigorous validation before it is made available for use in the global pandemic response.